These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14704106)

  • 1. Point: It's never too soon.
    Dawson NA
    Can J Urol; 2003 Dec; 10(6):2036-7. PubMed ID: 14704106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage prostate cancer treatment options.
    Cancer Pract; 1997; 5(1):11-6. PubMed ID: 9128491
    [No Abstract]   [Full Text] [Related]  

  • 3. How to implement the multidisciplinary approach in prostate cancer management: the Belgian model.
    Van Belle S
    BJU Int; 2008 Mar; 101 Suppl 2():2-4. PubMed ID: 18307685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of advanced prostate cancer: a multidisciplinary team approach.
    Bellmunt Molins J; Gelabert i Mas A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):977-9. PubMed ID: 17627457
    [No Abstract]   [Full Text] [Related]  

  • 5. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.
    Wallace K; Fleshner N; Jewett M; Basiuk J; Crook J
    J Clin Oncol; 2006 Sep; 24(25):4158-62. PubMed ID: 16943531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of patient-doctor dialog in the treatment of early prostate cancer.
    Fourcade RO; Mensink P; Ernemo B; Ligensa C
    Prostate Cancer Prostatic Dis; 2002; 5 Suppl 2():S12-4. PubMed ID: 12496991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer clinic improves time to treatment.
    Perform Improv Advis; 2003 Jun; 7(6):87-8, 81. PubMed ID: 13677871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of content completeness and accuracy of prostate cancer patient education materials.
    Walling AM; Maliski S; Bogorad A; Litwin MS
    Patient Educ Couns; 2004 Sep; 54(3):337-43. PubMed ID: 15324985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating a decision aid for patients with localized prostate cancer in clinical practice.
    Isebaert S; Van Audenhove C; Haustermans K; Junius S; Joniau S; De Ridder K; Van Poppel H
    Urol Int; 2008; 81(4):383-8. PubMed ID: 19077396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High risk prostate cancer: evolving definition and approach to management.
    Chughtai B; Mian BM
    Can J Urol; 2008 Dec; 15(6):4375-80. PubMed ID: 19046490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer: a chronic illness.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2007 Dec; 11(6):857-61. PubMed ID: 18063544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of consultant decision-making in the management of prostate cancer.
    Wilson J; Kennedy K; Ewings P; Macdonagh R
    Prostate Cancer Prostatic Dis; 2008; 11(3):288-93. PubMed ID: 17968424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
    Carducci MA; Carroll PR
    Urology; 2005 May; 65(5 Suppl):18-22; discussion 22. PubMed ID: 15885275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification.
    Thompson IM
    J Urol; 2006 Dec; 176(6 Pt 2):S21-4; discussion S25-6. PubMed ID: 17084160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone-refractory prostate cancer: a primer for the primary care physician.
    Potvin K; Winquist E
    Can J Urol; 2008 Aug; 15 Suppl 1():14-20; discussion 20. PubMed ID: 18700061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote.
    Denberg TD; Melhado TV; Steiner JF
    Cancer; 2006 Aug; 107(3):620-30. PubMed ID: 16802287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
    Hammerer PG; Kattan MW; Mottet N; Prayer-Galetti T
    BJU Int; 2006 Jul; 98(1):11-9. PubMed ID: 16566811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.